Management of chronic hepatitis B infection

摘要: Hepatitis B virus (HBV) is a global health problem that can lead to cirrhosis and hepatocellular carcinoma (HCC). Although HBV vaccination has reduced the prevalence Of infection, burden of disease remains high. Treatment with antiviral drugs reduces risk liver development HCC, it even reverse fibrosis. However, challenges remain regarding optimal timing, as well modality duration treatment. Currently approved include pegylated interferon nucleos(t)ide analogs. Nucleos(t)ide analogs are better tolerated provide excellent viral suppression low resistance, but offers benefit finite Monitoring hepatitis surface antigen (HBsAg) levels may help predict likelihood response treatment, particularly for interferon. Prolonged treatment usually needed oral agents, relapse common if discontinued. New treatments result in sustained clearance DNA HBsAg needed.